U.S. Sen. John Kennedy's (R-La.) failed amendment to the Inflation Reduction Act would have required health centers to make insulin and EpiPens available at or below 340B price and would have helped cover centers' direct costs of doing so. A leading health center advocate panned the amendment.

Senate Rejects 340B-Related Amendment to Major Drug Pricing and Climate Change Bill

The U.S. Senate on Sunday rejected a Republican amendment to Democratic drug pricing and climate change legislation that would have required federally qualified health centers to make insulin and injectable epinephrine available to patients at or below 340B price.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report